

Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission

*Emmanuel Ifeanyi Obeagu¹, Nwanganga Ihuoma Ubosi², Getrude Uzoma Obeagu³ and Muhammad Akram⁴

¹Department of Medical Laboratory Science, Kampala International University, Uganda.

²Department of Public Health Sciences, Faculty of Health Sciences, National Open University of Nigeria, Headquarters, Jabi, Abuja, Nigeria.

³School of Nursing Science, Kampala International University, Uganda.

⁴Department of Eastern Medicine, Government College University, Faisalabad, Pakistan

*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug

Abstract

Early Infant Diagnosis (EID) stands as a cornerstone in the global strategy to eradicate pediatric Human Immunodeficiency Virus (HIV) infections. This review delves into the pivotal role of EID in preventing the transmission of HIV from mothers to infants, emphasizing its significance in breaking the chain of transmission. The exploration encompasses key strategies such as Nucleic Acid Testing and Point-of-Care Testing, the integration of EID into broader Prevention of Mother-to-Child Transmission programs, and the persistent challenges hindering its full implementation. The review also sheds light on the latest technological advancements in EID, offering hope for improved efficiency and accessibility. As we navigate the complexities of accessibility barriers, loss to follow-up challenges, and turnaround time concerns, the review underscores the need for continued research, innovation, and global collaboration to ensure the successful implementation of EID and the realization of an HIV-free generation.

Citation: Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*, 2024; 2 (1): 52-61

Keywords: *Early Infant Diagnosis, Pediatric HIV Prevention, Nucleic Acid Testing, Point-of-Care Testing, Technological Advancements, Global Collaboration, HIV-Free Generation*

Introduction

In the relentless pursuit of global health equity, the prevention of mother-to-child transmission (PMTCT) of Human Immunodeficiency Virus (HIV) has emerged as a critical battleground. At the heart of this endeavor lies Early Infant Diagnosis (EID), a linchpin in the arsenal against pediatric HIV infections.¹⁻⁵ HIV remains a formidable public health challenge, with an estimated 1.5 million pregnant women living with the virus globally. Without intervention, the risk of mother-to-child transmission looms large, underscoring the urgency of implementing robust PMTCT strategies. Among these, EID emerges as a beacon of hope, offering a proactive approach to identify HIV-infected infants swiftly and initiate timely interventions, thereby altering the trajectory of their health outcomes.⁵⁻¹⁰

As nations strive to achieve the Sustainable Development Goal of ending the HIV/AIDS epidemic by 2030, the focus on PMTCT has intensified. Within this framework, EID stands as a crucial pillar, aiming not only to diagnose infants promptly but also to interrupt the cycle of transmission at its inception.¹¹ Early Infant Diagnosis provides the gateway to early identification of HIV in infants, paving the way for prompt initiation of Antiretroviral Therapy (ART). The significance of early treatment cannot be overstated, as it has been proven to substantially reduce morbidity and mortality rates among HIV-positive infants, offering them a lifeline towards a healthier future.¹²⁻¹⁵

Importance of Early Infant Diagnosis

The importance of Early Infant Diagnosis (EID) in the context of HIV cannot be overstated, as it serves as a pivotal tool in breaking the chain of transmission and ensuring the well-being of HIV-exposed infants. Early Infant Diagnosis (EID) enables the prompt detection of HIV in infants, typically within the first few weeks of life. This early identification is crucial as it allows healthcare providers to initiate interventions before the onset of severe symptoms, significantly impacting the child's health outcomes.¹⁶ Early diagnosis through EID facilitates the timely initiation of Antiretroviral Therapy (ART). ART has been shown to suppress the replication of the virus, preserving the immune system and improving the long-term prognosis for HIV-infected infants. Early treatment can mitigate the progression of the disease and reduce the risk of opportunistic infections. The timely administration of ART, made possible by EID, has been associated with a substantial reduction in morbidity and mortality rates among HIV-infected infants. Early intervention enhances the child's chances of leading a healthier and more productive life.

EID is a crucial component of Prevention of Mother-to-Child Transmission (PMTCT) programs, contributing to the broader strategy of preventing the transmission of HIV from mothers to their infants. By identifying infected infants early in life, EID supports targeted interventions to break

Citation: Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*, 2024; 2 (1): 52-61

the cycle of transmission and protect future generations from the scourge of HIV.¹⁷⁻²¹ EID provides an opportunity for healthcare providers to offer counseling and support to families affected by HIV. Early knowledge of a child's HIV status allows families to make informed decisions about caregiving, treatment adherence, and family planning, empowering them to navigate the complexities of living with HIV. Implementing EID on a global scale contributes to the broader public health goal of reducing the overall burden of HIV. By preventing new pediatric infections and improving the health of HIV-infected infants, EID plays a vital role in advancing global efforts to control and eventually eliminate HIV/AIDS. EID aids in the strategic allocation of healthcare resources by identifying those infants who require immediate attention and intervention. This targeted approach ensures that resources, including medications and healthcare personnel, are directed to where they are most needed, optimizing the efficiency of healthcare systems.

Strategies for Early Infant Diagnosis

The implementation of effective strategies for Early Infant Diagnosis (EID) is critical in ensuring the timely identification of HIV in infants and initiating appropriate interventions. Several key strategies contribute to the success of EID programs: Utilizing highly sensitive techniques, such as Polymerase Chain Reaction (PCR), for nucleic acid testing is a cornerstone of EID. Nucleic Acid Testing (NAT) allows for the detection of HIV genetic material in infant blood samples, providing accurate and reliable results. This method is commonly employed in centralized laboratories equipped with the necessary infrastructure.²² Point-of-Care Testing is a revolutionary strategy that brings diagnostic capabilities directly to healthcare facilities or community settings. Rapid and on-site tests, often utilizing technologies like lateral flow assays, allow for immediate results without the need for transportation of samples to centralized laboratories. Point-of-Care Testing (POCT): is particularly valuable in resource-limited settings, enhancing accessibility to diagnostic services.²³

Integrating EID services seamlessly into broader Prevention of Mother-to-Child Transmission (PMTCT) programs enhances overall effectiveness. Combining prenatal care, HIV testing for pregnant women, and EID within maternal and child health programs ensures a comprehensive approach. This integration facilitates the seamless transition of care from pregnancy through childbirth and the postnatal period.²⁴⁻²⁸ Educating pregnant women about the importance of EID and the PMTCT continuum is crucial. Raising awareness about the benefits of early diagnosis, treatment options, and the positive impact on infant health encourages pregnant women to participate in EID programs voluntarily. Innovations in sample collection techniques, such as dried blood spot (DBS) cards, simplify the process of specimen collection in remote or resource-constrained areas. DBS cards allow for the collection, storage, and transportation of blood samples without the need for complex infrastructure, facilitating broader access to EID services. Ensuring that healthcare professionals are well-trained in EID protocols is essential for the successful implementation of diagnostic services. Continuous training programs and capacity-building initiatives contribute to the proficiency of healthcare workers, enhancing the quality and accuracy of EID results.

Citation: Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*, 2024; 2 (1): 52-61

Engaging communities in the importance of EID fosters a supportive environment for testing and treatment adherence. Community mobilization initiatives, including outreach programs and community health workers, play a vital role in connecting families with EID services and addressing potential barriers to access.²⁹ Establishing robust quality assurance mechanisms and strengthening laboratory infrastructure are pivotal for the reliability of EID results. Regular monitoring, proficiency testing, and adherence to international standards contribute to the accuracy of diagnostic services. Leveraging digital health technologies, such as mobile applications and telehealth services, can facilitate communication, data management, and follow-up care. These solutions enhance the efficiency of EID programs and improve the overall patient experience.

Challenges in Implementing Early Infant Diagnosis

Despite the critical role that Early Infant Diagnosis (EID) plays in preventing pediatric HIV infections, several challenges hinder its successful implementation. In many regions, particularly in rural and remote areas, access to healthcare facilities equipped with EID services is limited. This geographical barrier hampers the timely identification of HIV-infected infants, as families may face challenges in reaching testing facilities. After initial testing, infants diagnosed with HIV may face difficulties in staying connected to care. Factors such as transportation issues, socioeconomic barriers, and stigma contribute to the loss of follow-up, impeding the continuity of care and treatment.³⁰⁻³⁴ The prolonged turnaround time for EID test results can be a significant challenge. Delays in providing results to caregivers may hinder the prompt initiation of treatment, potentially impacting the health outcomes of HIV-infected infants.

In resource-limited settings, a shortage of trained healthcare professionals can impede the implementation of EID programs. Limited human resources may lead to delays in sample processing, result reporting, and counseling services. Cultural beliefs and stigmas associated with HIV can deter families from seeking EID services. Fear of discrimination and social isolation may lead to delayed or incomplete participation in EID programs. Inadequate infrastructure, including transportation and storage facilities, poses challenges in maintaining the integrity of blood samples during transportation to centralized laboratories. Supply chain issues may also affect the availability of testing kits and other necessary materials.³⁵⁻³⁹ The cost of EID services, including testing and follow-up care, can be a significant barrier for families with limited financial resources. Affordability issues may result in delayed or insufficient access to essential healthcare services. Linking maternal and infant healthcare records can be challenging, particularly in settings where healthcare systems may lack interoperability. Ensuring a seamless transition of care from prenatal to postnatal services is crucial for effective EID. Failure to integrate EID services into broader maternal and child health programs can result in missed opportunities for testing and treatment. The lack of coordination may lead to fragmented care and reduced program efficiency. Limited awareness among healthcare providers and communities about the importance of EID can hinder its uptake. Educational gaps regarding testing procedures, treatment options, and the overall significance of EID need to be addressed to improve program acceptance and adherence.

Technological Advancements in Early Infant Diagnosis

Citation: Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*, 2024; 2 (1): 52-61

Technological advancements have significantly transformed Early Infant Diagnosis (EID), enhancing the accuracy, efficiency, and accessibility of diagnostic services. These innovations play a crucial role in breaking the chain of HIV transmission by allowing for rapid and reliable identification of HIV-infected infants. Next-Generation Sequencing (NGS) technologies have revolutionized genomic analysis, allowing for high-throughput sequencing of DNA.⁴⁰ In the context of EID, NGS can provide detailed genetic information about the virus, aiding in the identification of drug-resistant strains and informing treatment decisions. Dried Blood Spot (DBS) technology involves collecting and storing blood samples on filter paper, facilitating easy transportation and storage.⁴¹ This method is particularly valuable in resource-limited settings where access to sophisticated sample handling infrastructure is limited. Loop-Mediated Isothermal Amplification (LAMP) is an isothermal nucleic acid amplification technique that allows for the rapid and sensitive detection of viral DNA.⁴² This technology is well-suited for point-of-care testing, providing quick results without the need for complex laboratory equipment.

Digital PCR (dPCR) offers improved sensitivity and precision in detecting viral nucleic acids. It enables the absolute quantification of target DNA, enhancing the accuracy of HIV detection in infant samples. Portable and user-friendly Point-of-Care Testing (POCT) devices enable rapid on-site testing, reducing the turnaround time for results. These devices, often utilizing lateral flow assays or other rapid testing technologies, are particularly beneficial in remote or resource-limited settings.⁴¹ Mobile Health (mHealth) solutions leverage mobile technologies to enhance communication, data management, and follow-up care. SMS reminders, mobile applications, and telehealth services contribute to improved patient engagement and adherence to EID programs. Biosensors and microfluidic devices offer miniaturized and highly sensitive platforms for detecting viral markers. These technologies enable precise and rapid analysis of small sample volumes, making them suitable for point-of-care applications. Dedicated EID platforms integrate multiple testing components into a single system, streamlining the diagnostic process. These platforms often include sample preparation, amplification, and detection modules, providing a comprehensive solution for EID. Artificial Intelligence (AI) algorithms are increasingly employed for data analysis in EID. These technologies can assist in interpreting complex genetic data, predicting drug resistance patterns, and optimizing treatment regimens based on individual patient characteristics. Multiplexed testing allows for the simultaneous detection of multiple pathogens or genetic markers. This approach is beneficial in diagnosing co-infections or identifying specific HIV strains, contributing to a more comprehensive understanding of the viral landscape.

Conclusion

EID stands as a cornerstone in the global effort to prevent pediatric HIV infections. The ability to identify and treat HIV-infected infants in the earliest stages of life transforms the trajectory of their health outcomes, contributing to the vision of an HIV-free generation. Robust strategies, including Nucleic Acid Testing, Point-of-Care Testing, integrated PMTCT programs, and innovative technologies, collectively enhance the effectiveness of EID. These approaches address challenges such as limited access, loss to follow-up, and turnaround time concerns, fostering a comprehensive and patient-centered approach.

Citation: Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*, 2024; 2 (1): 52-61

In the grand tapestry of the global response to HIV/AIDS, EID emerges as a beacon of hope, promising a future where no infant needlessly bears the burden of this preventable and treatable virus. Through the collective endeavors of healthcare professionals, researchers, policymakers, and communities, the vision of an HIV-free generation can be transformed into reality. The ongoing commitment to breaking the chain of HIV transmission through Early Infant Diagnosis represents a testament to the resilience and determination of the global health community in the face of one of humanity's most significant challenges.

References

1. Yamin AE. When misfortune becomes injustice: Evolving human rights struggles for health and social equality. Stanford University Press; 2023.
2. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
3. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-18.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
4. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
5. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
6. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
7. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
8. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
9. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
10. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community

Citation: Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61

- Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
11. Prendergast AJ, Essajee S, Penazzato M. HIV and the millennium development goals. *Archives of disease in childhood*. 2015;100(Suppl 1):S48-52.
 12. World Health Organization. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013.
 13. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
 14. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
 15. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
 16. Ghadrshenas A, Amor YB, Chang J, Dale H, Sherman G, Vojnov L, Young P, Yogev R, Child Survival Working Group of the Interagency Task Team on the Prevention and Treatment of HIV infection in Pregnant Women, Mothers and Children. Improved access to early infant diagnosis is a critical part of a child-centric prevention of mother-to-child transmission agenda. *Aids*. 2013;27:S197-205.
 17. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf.
 18. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
 19. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf)
 20. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.
 21. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanja CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban

Citation: Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*, 2024; 2 (1): 52-61

- Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.
[links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](#).
22. Mangal M, Bansal S, Sharma SK, Gupta RK. Molecular detection of foodborne pathogens: a rapid and accurate answer to food safety. Critical reviews in food science and nutrition. 2016;56(9):1568-84.
23. Bissonnette L, Bergeron MG. Diagnosing infections—current and anticipated technologies for point-of-care diagnostics and home-based testing. Clinical Microbiology and Infection. 2010;16(8):1044-53.
24. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](#).
25. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144.
https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf.
26. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4.
[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](#)
27. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
28. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
29. Cataldo F, Sam-Agudu NA, Phiri S, Shumba B, Cornelius LJ, Foster G. The roles of expert mothers engaged in prevention of mother-to-child transmission (PMTCT) programs: a commentary on the INSPIRE studies in Malawi, Nigeria, and Zimbabwe. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;75:S224-32.
30. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139.
[links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](#).
31. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in
- Citation:** Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61

- Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
32. Walter O, Anaebio QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022;29-34.
 33. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
 34. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137.
[links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://www.researchgate.net/publication/361746114/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf).
 35. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://www.researchgate.net/publication/36516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf)
 36. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://www.researchgate.net/publication/36516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf).
 37. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014
https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
 38. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
 39. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. <http://ajdhs.com/index.php/journal/article/view/39>.
 40. Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, Thakare RP, Banday S, Mishra AK, Das G, Malonia SK. Next-generation sequencing technology: Current trends and advancements. Biology. 2023;12(7):997.

Citation: Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61

41. McDade TW. Development and validation of assay protocols for use with dried blood spot samples. American Journal of Human Biology. 2014;26(1):1-9.
42. Chander Y, Koelbl J, Puckett J, Moser MJ, Klingele AJ, Liles MR, Carrias A, Mead DA, Schoenfeld TW. A novel thermostable polymerase for RNA and DNA loop-mediated isothermal amplification (LAMP). Frontiers in Microbiology. 2014; 5:395.